These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Biomaterials in siRNA Delivery: A Comprehensive Review. Ho W; Zhang XQ; Xu X Adv Healthc Mater; 2016 Nov; 5(21):2715-2731. PubMed ID: 27700013 [TBL] [Abstract][Full Text] [Related]
4. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials. DeVincenzo JP Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462 [TBL] [Abstract][Full Text] [Related]
5. Powering up the molecular therapy of RNA interference by novel nanoparticles. Liao W; Li W; Zhang T; Kirberger M; Liu J; Wang P; Chen W; Wang Y Biomater Sci; 2016 Jun; 4(7):1051-61. PubMed ID: 27221980 [TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticles for short interfering RNA delivery. Leung AK; Tam YY; Cullis PR Adv Genet; 2014; 88():71-110. PubMed ID: 25409604 [TBL] [Abstract][Full Text] [Related]
8. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840 [TBL] [Abstract][Full Text] [Related]
9. Chitosan-based nanoparticles for mucosal delivery of RNAi therapeutics. Martirosyan A; Olesen MJ; Howard KA Adv Genet; 2014; 88():325-52. PubMed ID: 25409611 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting in the silent era: advances in non-viral siRNA delivery. Guo J; Fisher KA; Darcy R; Cryan JF; O'Driscoll C Mol Biosyst; 2010 Jul; 6(7):1143-61. PubMed ID: 20431817 [TBL] [Abstract][Full Text] [Related]
11. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Davis ME; Zuckerman JE; Choi CH; Seligson D; Tolcher A; Alabi CA; Yen Y; Heidel JD; Ribas A Nature; 2010 Apr; 464(7291):1067-70. PubMed ID: 20305636 [TBL] [Abstract][Full Text] [Related]
12. Nonviral delivery of synthetic siRNAs in vivo. Akhtar S; Benter IF J Clin Invest; 2007 Dec; 117(12):3623-32. PubMed ID: 18060020 [TBL] [Abstract][Full Text] [Related]
13. RNAi-based therapeutics and tumor targeted delivery in cancer. Kara G; Calin GA; Ozpolat B Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535 [TBL] [Abstract][Full Text] [Related]
14. Delivery vehicles for small interfering RNA in vivo. de Fougerolles AR Hum Gene Ther; 2008 Feb; 19(2):125-32. PubMed ID: 18257677 [TBL] [Abstract][Full Text] [Related]
15. Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: a promising approach in liver-specific RNAi delivery. Sajeesh S; Lee TY; Kim JK; Son DS; Hong SW; Kim S; Yun WS; Kim S; Chang C; Li C; Lee DK J Control Release; 2014 Dec; 196():28-36. PubMed ID: 25251899 [TBL] [Abstract][Full Text] [Related]
16. Nanoparticle Delivery Platforms for RNAi Therapeutics Targeting COVID-19 Disease in the Respiratory Tract. Zhang Y; Almazi JG; Ong HX; Johansen MD; Ledger S; Traini D; Hansbro PM; Kelleher AD; Ahlenstiel CL Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269550 [TBL] [Abstract][Full Text] [Related]
17. Delivery of RNAi mediators. Ford LP; Toloue MM Wiley Interdiscip Rev RNA; 2010; 1(2):341-50. PubMed ID: 21935894 [TBL] [Abstract][Full Text] [Related]
19. A novel therapeutic strategy for cartilage diseases based on lipid nanoparticle-RNAi delivery system. Wang S; Wei X; Sun X; Chen C; Zhou J; Zhang G; Wu H; Guo B; Wei L Int J Nanomedicine; 2018; 13():617-631. PubMed ID: 29440889 [TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-based delivery system for application of siRNA in vivo. Wang Y; Li Z; Han Y; Liang LH; Ji A Curr Drug Metab; 2010 Feb; 11(2):182-96. PubMed ID: 20359287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]